MedTrace Logo

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

NCT01882803 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2023-09-07

Study results available
· View outcomes & findings →

Summary

This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma \[FL\], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherapy or radioimmunotherapy (RIT).

Conditions

  • Indolent Non-Hodgkin Lymphoma

Interventions

DRUG

Duvelisib

Phosphoinositide-3-kinase (PI3K) inhibitor

Sponsors & Collaborators

  • SecuraBio

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-17
Primary Completion
2020-11-18
Completion
2020-11-18

Countries

  • United States
  • Belarus
  • Belgium
  • Bulgaria
  • Canada
  • Czechia
  • France
  • Georgia
  • Hungary
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01882803 on ClinicalTrials.gov